top of page
Executive Spotlights

Sanofi to buy INBRX-101 for $2.2B

La Jolla, CA & Paris, France, January 23, 2024 (Reuters) -- Sanofi (SASY.PA) has reached an agreement to acquire U.S. Inhibrx (INBX.O) in a transaction valued at up to $2.2 billion. This strategic move aims to enhance Sanofi's drug development portfolio by incorporating an experimental treatment for a rare genetic disease, namely Inhibrx's INBRX-101. Under the terms of the agreement, Sanofi will gain access to INBRX-101, currently progressing through the second phase of clinical trials. Simultaneously, Inhibrx's other experimental drugs will be spun off into a separate entity, with Sanofi retaining an 8% stake in the newly formed company. This transaction aligns with Sanofi's commitment to advancing its therapeutic offerings and expanding its presence in the biotechnology sector.

Read full article here.

Recent Posts

See All
Life Science Headlines
bottom of page